A retrospective study of the lipid-lowering efficacy and safety of ezetimibe added to hydroxy methylglutaryl coenzyme A reductase therapy in HIV-infected patients with hyperlipidemia

• Published in: Journal of clinical lipidology 2007-12, Vol.1 (6), p.634-639
• Main Authors: Chastain, Lisa M., PharmD, Bain, Amy M., PharmD, Edwards, Krystal L., PharmD, BCPS, Bedimo, Roger, MD, MS, Busti, Anthony J., PharmD, BCPS
• Format: Article
• Language: English
• Subjects: Antiretroviral therapy; Cardiovascular; Dyslipidemia; Ezetimibe; Human immunodeficiency virus; Hydroxymethylglutaryl-Coenzyme A reductase inhibitor
• ISSN: 1933-2874; 1876-4789
• DOI: 10.1016/j.jacl.2007.10.003

Background Abnormalities in lipid metabolism are a well-described consequence of human immunodeficiency virus (HIV) infection being treated with highly active antiretroviral therapies (HAART). Objective The purpose of this study is to evaluate the lipid-lowering efficacy and safety of ezetimibe added to existing hydroxy methylglutaryl coenzyme A reductase (statin) therapy in HIV-infected patients with hyperlipidemia. Methods This is a retrospective study utilizing a comprehensive electronic patient registry to identify all adult HIV-infected patients seen at the Dallas Veterans Affairs (VA) Medical Center during a 4-year period from October 1, 2002 through October 1, 2006. Results A total of 26 HIV-infected patients initiated on ezetimibe 10 mg were identified, with 14 adult males meeting strict criteria for inclusion. Median age was 54 years (interquartile range [IQR], 45–59) with a median duration of HIV of 13 years, CD4 count of 513 cells/mm3 (IQR, 289–736), and 9 of 14 patients had undetectable viral loads at baseline. Initiation of ezetimibe 10 mg resulted in a significant decrease in total cholesterol (TC) from baseline (−12.9%, P = 0.001); low-density lipoprotein cholesterol (LDL-C; −25.7%, P = 0.001); and non–high-density lipoprotein cholesterol (non–HDL-C; −23.9%, P = 0.001). There was also a nonsignificant decrease in triglycerides (15.8%, P = 0.43), and an increase in number of patients achieving National Cholesterol Education Program/Adult Treatment Panel III goal for LDL-C after initiation of ezetimibe (+20.9%, P = 0.125). These improvements occurred without adverse effects or changes in virologic and immunologic control. Conclusion Addition of ezetimibe to existing statin therapy in HIV-infected VA patients treated with HAART significantly reduces TC, LDL-C, and non–HDL-C concentrations without apparent side effects or compromising of virologic control.